Decrease post-transplant relapse using donor-derived expanded NK-cells.
Adolescent
Adult
Aged
Case-Control Studies
Female
Follow-Up Studies
Hematologic Neoplasms
/ immunology
Hematopoietic Stem Cell Transplantation
/ mortality
Humans
Killer Cells, Natural
/ immunology
Male
Middle Aged
Neoplasm Recurrence, Local
/ immunology
Prognosis
Survival Rate
Transplantation Conditioning
Transplantation, Haploidentical
Unrelated Donors
/ statistics & numerical data
Young Adult
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
29
04
2021
accepted:
12
07
2021
revised:
02
07
2021
pubmed:
28
7
2021
medline:
19
2
2022
entrez:
27
7
2021
Statut:
ppublish
Résumé
In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation (HSCT). Three doses of donor NK cells (1 × 10
Identifiants
pubmed: 34312462
doi: 10.1038/s41375-021-01349-4
pii: 10.1038/s41375-021-01349-4
pmc: PMC8727305
mid: NIHMS1739240
doi:
Banques de données
ClinicalTrials.gov
['NCT01904136']
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
155-164Subventions
Organisme : NCI NIH HHS
ID : P01 CA049639
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016058
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Copelan EA. Hematopoietic stem-cell transplantation. N. Engl J Med. 2006;354:1813–26.
doi: 10.1056/NEJMra052638
pubmed: 16641398
National Marrow Donor Program, a contractor for the C.W. Bill Young Cell Transplantation Program operated through the US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. Donor Registry Transplant Data. Last Updated: April 15, 2021.
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl J Med. 2010;363:2091–101.
doi: 10.1056/NEJMoa1004383
pubmed: 21105791
pmcid: 3017343
Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone marrow Transplant. 2020;55:126–36.
doi: 10.1038/s41409-019-0624-z
pubmed: 31455899
Ciurea SO, Labopin M, Socie G, Volin L, Passweg J, Chevallier P, et al. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for blood and marrow transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018;124:2134–41.
doi: 10.1002/cncr.31311
pubmed: 29469961
Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–21.
doi: 10.1182/blood-2013-06-506725
pubmed: 23847197
pmcid: 3765060
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503–10.
doi: 10.1038/ni1582
pubmed: 18425107
Ruggeri L, Parisi S, Urbani E, Curti A. Alloreactive natural killer cells for the treatment of acute myeloid leukemia: from stem cell transplantation to adoptive immunotherapy. Front Immunol. 2015;6:479.
doi: 10.3389/fimmu.2015.00479
pubmed: 26528283
pmcid: 4606119
Farhan S, Lee DA, Champlin RE, Ciurea SO. NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy. 2012;4:305–13.
doi: 10.2217/imt.11.174
pubmed: 22329587
Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One. 2012;7:e30264.
doi: 10.1371/journal.pone.0030264
pubmed: 22279576
pmcid: 3261192
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130:1857–68.
doi: 10.1182/blood-2017-05-785659
pubmed: 28835441
pmcid: 5649552
Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone marrow Transplant. 2020;55:12–24.
doi: 10.1038/s41409-019-0499-z
pubmed: 30833742
Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116:2411–9.
doi: 10.1182/blood-2010-05-283051
pubmed: 20581313
pmcid: 2953880
Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl J Med. 2012;367:805–16.
doi: 10.1056/NEJMoa1200503
pubmed: 22931314
pmcid: 3767478
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, et al. Complement-binding donor-specific Anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21:1392–8.
doi: 10.1016/j.bbmt.2015.05.001
Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. Correction: the European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific Anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone marrow Transplant. 2019;54:784.
doi: 10.1038/s41409-018-0332-0
pubmed: 30232413
Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, et al. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica. 2020. https://doi.org/10.3324/haematol.2019.227371
Streltsova MA, Erokhina SA, Kanevskiy LM, Grechikhina MV, Kobyzeva PA, Lee DA, et al. Recurrent stimulation of natural killer cell clones with K562 expressing membrane-bound interleukin-21 affects their phenotype, interferon-γ production, and lifespan. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20020443
Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131:247–62.
doi: 10.1182/blood-2017-05-780668
pubmed: 28986344
pmcid: 5757695
Makanga DR, Guillaume T, Willem C, Legrand N, Gagne K, Cesbron A, et al. Posttransplant cyclophosphamide and antithymocyte globulin versus posttransplant cyclophosphamide as graft-versus-host disease prophylaxis for peripheral blood stem cell haploidentical transplants: comparison of T cell and NK effector reconstitution. J Immunol. 2020;205:1441–8.
doi: 10.4049/jimmunol.2000578
pubmed: 32747504
Willem C, Makanga DR, Guillaume T, Maniangou B, Legrand N, Gagne K, et al. Impact of KIR/HLA incompatibilities on NK Cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide. J Immunol. 2019;202:2141–52.
doi: 10.4049/jimmunol.1801489
pubmed: 30787107
Ciurea SO, Bassett R, Soebbing D, Rondon G, Cao K, Olson AL, et al. Improved outcomes for patients receiving high-doses of IL-21 ex vivo expanded NK cells after haploidentical transplantation (haploSCT): long-term follow-up of a phase 1/2 clinical trial with comparison to CIBMTR controls. Blood. 2019;134:700–700.
doi: 10.1182/blood-2019-123936
Baker M, Wang H, Rowley SD, Cai L, Pecora AL, Skarbnik A, et al. Comparative outcomes after haploidentical or unrelated donor bone marrow or blood stem cell transplantation in adult patients with hematological malignancies. Biol Blood Marrow Transpl. 2016;22:2047–55.
doi: 10.1016/j.bbmt.2016.08.003